HNSCC
Clinical trials for HNSCC explained in plain language.
Never miss a new study
Get alerted when new HNSCC trials appear
Sign up with your email to follow new studies for HNSCC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo targets genetic flaws in Tough-to-Treat head and neck cancer
Disease control CompletedThis early-phase trial tested the safety and initial effectiveness of a two-drug combination (tipifarnib and alpelisib) for adults with advanced head and neck cancer that had returned or spread. The study focused on patients whose tumors had specific genetic markers (HRAS or PIK3…
Matched conditions: HNSCC
Phase: PHASE1, PHASE2 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New combo therapy tested in battle against tough head & neck cancers
Disease control CompletedThis study tested whether adding a new immunotherapy drug (eftilagimod alpha) to a standard treatment (pembrolizumab) works better for people with advanced head and neck cancer that has spread or returned. It involved 171 participants who had not yet received treatment for their …
Matched conditions: HNSCC
Phase: PHASE2 • Sponsor: Immutep S.A.S. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New drug duo tested for Tough-to-Treat head and neck cancers
Disease control CompletedThis study tested whether combining two existing cancer drugs, pembrolizumab and cetuximab, could help control advanced head and neck cancer that had returned or spread. It involved 78 patients at four US cancer centers, grouped based on their prior treatments. The main goal was …
Matched conditions: HNSCC
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Cancer trial questions: can patients stop treatment after one year?
Disease control CompletedThis study aimed to find the best length of immunotherapy treatment for people with advanced cancers. It enrolled 161 patients whose cancer had remained stable after one year of treatment. Researchers randomly assigned participants to either stop their immunotherapy or continue i…
Matched conditions: HNSCC
Phase: PHASE3 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC
-
New weapon added to fight aggressive head & neck cancer after surgery
Disease control CompletedThis study tested if adding a newer immunotherapy drug (pembrolizumab) to the standard post-surgery treatment (chemotherapy plus radiation) works better for patients with high-risk head and neck cancer. It involved 211 patients who had surgery but were at high risk of the cancer …
Matched conditions: HNSCC
Phase: PHASE2 • Sponsor: University of Leipzig • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC
-
Early trial tests natural supplement to ease agony of cancer treatment
Symptom relief CompletedThis early-stage study tested whether a dietary supplement called alpha lipoic acid could help reduce pain and mouth sores for people undergoing combined chemotherapy and radiation for head and neck cancer. Five patients participated to find the safest and most effective dose. Th…
Matched conditions: HNSCC
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Symptom relief
Last updated Apr 01, 2026 22:41 UTC